Skip to main content
Clinical Trials/NCT02041624
NCT02041624
Terminated
Not Applicable

An International Non-Interventional Registry on the Quality of Life of Patients With Grass-pollen-induced Allergic Rhinitis Treated With Oralair®.

Stallergenes Greer1 site in 1 country740 target enrollmentMay 2014

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Allergic Rhinitis Due to Grass Pollens
Sponsor
Stallergenes Greer
Enrollment
740
Locations
1
Primary Endpoint
Health related quality of life
Status
Terminated
Last Updated
10 years ago

Overview

Brief Summary

The purpose of the present study is to describe patient's perception of quality of life and effectiveness of ORALAIR® over a follow-up period up to 5 years, in real-life settings.

Detailed Description

Primary objective: To describe the patient's perception of the impact of ORALAIR® on his/her health related generic and disease specific quality of life during the grass pollen season in real-life settings. Secondary objectives: - To describe the patient's perceived effectiveness of ORALAIR® in allergic rhinoconjunctivitis management in terms of disease intensity, satisfaction and rescue medication

Registry
clinicaltrials.gov
Start Date
May 2014
End Date
December 2015
Last Updated
10 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patient of 5 years of age and older at the date of the screening visit
  • Patient with proven allergic rhino-conjunctivitis due to grass pollen
  • Patient eligible for a grass-pollen Allergen ImmunoTherapy (AIT)
  • Patient whose physician prescribed ORALAIR® independently of the study, before the beginning of the grass-pollen season

Exclusion Criteria

  • Patient participating in a clinical trial or in an epidemiological study

Outcomes

Primary Outcomes

Health related quality of life

Time Frame: patients will be followed for the duration of the treatment, an expected average of 6 months/year

The primary objective is to describe the patient's perception of the impact of ORALAIR® on his/her health related generic and disease specific quality of life during the grass-pollen season in real-life settings.

Secondary Outcomes

  • Treatment Effectiveness(patients will be followed for the duration of the treatment, an expected average of 6 months/year)

Study Sites (1)

Loading locations...

Similar Trials